NEW YORK (GenomeWeb News) – The proprietary collections of genetic testing data amassed by US diagnostics companies effectively give them competitive advantages and can negatively impact the testing market and make it harder for doctors to interpret patient results, according to a paper published today in the online edition of the European Journal of Human Genetics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.